Extensive 177Lu-PSMA Radioligand Therapy Can Lead to Radiation Nephropathy with a Renal Thrombotic Microangiopathy-like Picture.

Abstract

Lutetium-177 prostate-specific membrane antigen (177Lu-PSMA) radioligand therapy is an option that is increasingly being used for treatment of metastatic castration-resistant prostate cancer. This delivers β-radiation to cells expressing PSMA and high accumulation of the radiopharmaceutical occurs in the kidneys. Here we report three cases of radiation nephropathy with severe chronic kidney disease induced by renal thrombotic microangiopathy following extensive treatment with 177Lu-PSMA radioligand therapy.

• Authors: Hannah Schäfer, Sarah Mayr, Maike Büttner-Herold, Karina Knorr, Lisa Steinhelfer, Carsten A Böger, Jürgen E Gschwend, Uwe Heemann, Matthias Eiber, Christoph Schmaderer, Robert Tauber
• Journal: European urology (Eur Urol) Vol. 83 Issue 5 Pg. 385-390 (05 2023) ISSN: 1873-7560 [Electronic] Switzerland
• PMID: 35688660 (Publication Type: Case Reports)
• Copyright: Copyright © 2022 European Association of Urology. Published by Elsevier B.V. All rights reserved.

Chemical References

• Prostate-Specific Antigen
• Dipeptides
• Lutetium

Topics

• Male
• Humans
• Prostate-Specific Antigen
• Prostatic Neoplasms, Castration-Resistant (radiotherapy, pathology)
• Dipeptides
• Kidney (pathology)
• Lutetium (therapeutic use)
• Thrombotic Microangiopathies
• Treatment Outcome